预约演示
更新于：2025-05-26
Caspofungin Acetate
醋酸卡泊芬净
更新于：2025-05-26
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2001-01-26), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C54H92N10O17 |
InChIKeyAQCCMGSEGRTYBC-OHMBPTQSSA-N |
CAS号179463-17-3 |
Sequence Code 525965680
关联
87
项与 醋酸卡泊芬净 相关的临床试验NCT06892951
Phase I/II Safety Lead-in Randomized Blind Placebo-controlled Clinical Trial: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia in Adjunction of Conventional Systemic Antifungal Therapy
IRCT20231219060471N1
The comparison efficacy and safety of topical caspofungin ?.5% and topical voriconazole 1% in fungal keratitis
ChiCTR2300074819
Observation on the Safety and Efficacy of Different Doses of Caspofungin against Aspergillus Infection
100 项与 醋酸卡泊芬净 相关的临床结果
登录后查看更多信息
100 项与 醋酸卡泊芬净 相关的转化医学
登录后查看更多信息
100 项与 醋酸卡泊芬净 相关的专利（医药）
登录后查看更多信息
5,041
项与 醋酸卡泊芬净 相关的文献（医药）2025-12-01MEDICAL MICROBIOLOGY AND IMMUNOLOGY
The efficacy of antimicrobial therapies in the treatment of mixed biofilms formed between Candida albicans and Porphyromonas gingivalis during epithelial cell infection in the aspiration pneumonia model
Article
作者: Bras, Grazyna ; Satala, Dorota ; Juszczak, Magdalena ; Karkowska-Kuleta, Justyna ; Koziel, Joanna ; Kulig, Kamila ; Wronowska, Ewelina ; Rapala-Kozik, Maria ; Budziaszek, Joanna ; Sidlo, Wiktoria ; Surowiec, Magdalena ; Gonzalez-Gonzalez, Miriam
Abstract:
Aspiration pneumonia is a serious respiratory condition, which is particularly prevalent in patients with dysphagia, neurological disorders, or those undergoing surgical interventions. The formation of multispecies biofilms in the oral cavity, involving the bacterial periodontopathogen Porphyromonas gingivalis and the opportunistic pathogenic fungus Candida albicans, may also be related to the development of this serious disease, contributing also to the resistance to standard antimicrobial treatment. Therefore, this research aimed to evaluate the efficacy of selected antibiotics‒levofloxacin, metronidazole, meropenem, vancomycin‒and antifungal agents‒amphotericin B, caspofungin, and fluconazole‒on these mixed biofilms in the aspiration pneumonia model. While metronidazole and levofloxacin effectively inhibited bacterial viability in the mixed biofilms, lower doses increased release of bacterial proteases. In the conditions of mixed biofilms meropenem and vancomycin showed reduced efficacy, requiring significantly higher doses to achieve similar effect in mixed biofilms as in single bacterial cultures. Treatment with antifungals revealed that amphotericin B significantly impacted fungal cell viability within mixed biofilms, and this effect was enhanced when the antifungal drug was applied in the presence of P. gingivalis. Caspofungin and fluconazole showed variable efficacy, with caspofungin being more effective against C. albicans cells within biofilm.These findings indicated that due to the mutual microbial protection in the mixed-species biofilm, P. gingivalis retained its virulence despite increasing antibiotic doses. However, no excessive benefit of mixed biofilms was observed for C. albicans in the presence of antifungals, indicating the minor importance of yeasts in aspiration pneumonia development and their protective role for other pathogens in mixed-species infection.Graphical abstract
2025-11-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Tracking chemical interactions of caspofungin on silver nanoparticles through SERS spectroscopy for antifungal applications
Article
作者: da Silva Ferreira, Veronica ; da Silva Paschoal, Diego Fernando ; Sant'Anna, Celso B ; Sant'Ana, Antonio Carlos ; Coppoli Lanferini, Daphne F ; Borges, Francis Moreira
Silver nanoparticles (AgNP) act as efficient drug delivery carriers due to particular surface chemistry and high surface area, and even though such may present toxicity in function of the size distribution and molecular ion coverage, have been receiving special attention for their inhibitory potential against bacteria and fungi. This study explored the use of AgNP to deliver the antifungal caspofungin (CFG) for in vitro combating Candida albicans. CFG molecules were coadsorbed with low-weight chitosan (LWC) on AgNP surfaces, in the presence and absence of 2-mercaptoethanol (ME) surface modifier. Surface-enhanced Raman scattering (SERS) spectroscopy was used both to monitor the adsorption process and to assess the synergistic interaction between the components in actions against fungal cultures, observed by checkerboard assays. Results showed significant lowering of minimum inhibitory concentration (MIC) values for the CFG-LWC-AgNP ternary mixture in comparison with CFG alone. Transmission Electron Microscopy (TEM) images provided insights about the mechanism of action of components of the ternary mixture. Spectral analysis of CFG by using FT-Raman, FTIR, and SERS spectroscopies identified distinct spectral patterns, indicating effective chemical interactions of CFG on AgNP surfaces. The vibrational assignment of such spectra was done based on Density Functional Theory (DFT) calculations. Such findings suggest that AgNP could be a promising platform for enhancing the efficacy of CFG drug against fungal infections.
2025-08-01VETERINARY RESEARCH COMMUNICATIONS
Mycological and molecular identification of mycoses involved in mastitis from Holstein dairy cattle with special reference to Candida albicans
Article
作者: Maher, Ahmed ; Elmorsy, Ekramy ; Elgendy, Asmaa A ; Hetta, Helal F ; Mustari, Afrina ; Marawan, Marawan A ; Hikal, Ahmed F ; Elbaghdady, Heba Allah ; Mohamed, Mohamed E ; Fayed, Hayat ; Abdeen, Ahmed ; Shoulah, Salma A ; Ibrahim, Ateya M ; Moustafa, Samar M ; Ibrahim, Samah F
Globally, mastitis is an incredibly devastating, multifactorial disease that affects the dairy industry. However, cases of mycotic mastitis in dairy cows have increased in recent years. This study aimed to investigate the prevalence of mycotic mastitis with special reference to Candida albicans in Holstein-Friesian dairy cows from some farms in Menoufia province, Egypt. For the study, 150 milk samples (n = 150, 20 from healthy cows and 130 from cows with subclinical and clinical mastitis) were collected from 15 smallholder dairy farms located in three localities (Quesina, Elbagour, and Shibin El-Kom) five farms from each. The samples were subjected to mycological culture and subsequently verified using traditional morphological and biochemical tests to confirm fungal characteristics followed by antimycotic susceptibility testing using Vitec 2 system. Finally, molecular identification was carried out via PCR and phylogenetic analysis. 27 samples out of 130 were positive for fungal culture representing (20.77%). Candida species were recorded the highest percentage (62.96%) of the detected fungi (17/27). In addition, C. albicans was the predominant species (3/27), which corresponds to 11.11%. Antifungal susceptibility testing of the fungal isolates showed the highest susceptibility to micafungin, followed by caspofungin (88.88% and 86.19%, respectively). However, the lowest susceptibility was noted against amphotericin B (50.55%). The three isolates of C. albicans were confirmed by PCR by amplifying the ITS region, which was then sequenced for phylogenetic analysis. The sequences have been deposited in GenBank under the following accession numbers: OR97266, OR97267, and OR97268. Our results indicate that Candida spp., especially C. albicans, is one of the major causes of mycotic mastitis in dairy cows in Egypt. Moreover, micafungin might be the efficient medication for treating these cases of mycotic mastitis, followed by caspofungin.
100 项与 醋酸卡泊芬净 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 侵袭性肺曲霉菌病 | 中国 | 2013-06-17 | |
| 肺曲霉菌病 | 日本 | 2012-01-18 | |
| 曲霉菌病 | 中国 | 2002-10-29 | |
| 中性粒细胞减少 | 中国 | 2002-10-29 | |
| 念珠菌病 | 美国 | 2002-09-20 | |
| 侵袭性念珠菌病 | 欧盟 | 2001-10-23 | |
| 侵袭性念珠菌病 | 冰岛 | 2001-10-23 | |
| 侵袭性念珠菌病 | 列支敦士登 | 2001-10-23 | |
| 侵袭性念珠菌病 | 挪威 | 2001-10-23 | |
| 真菌病 | 欧盟 | 2001-10-23 | |
| 真菌病 | 冰岛 | 2001-10-23 | |
| 真菌病 | 列支敦士登 | 2001-10-23 | |
| 真菌病 | 挪威 | 2001-10-23 | |
| 念珠菌血症 | 加拿大 | 2001-08-23 | |
| 食管念珠菌病 | 加拿大 | 2001-08-23 | |
| 侵袭性曲霉菌病 | 美国 | 2001-01-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 持续感染 | 临床3期 | - | 2005-06-01 | |
| 真菌血症 | 临床2期 | 意大利 | 2009-05-01 | |
| 粒细胞减少性发热 | 临床2期 | - | 2004-05-01 | |
| 发热 | 临床2期 | - | 2004-04-01 | |
| 侵袭性真菌感染 | 临床2期 | 西班牙 | 2003-10-01 | |
| 口腔念珠菌病 | 临床2期 | 美国 | 2001-08-31 | |
| HIV感染 | 临床2期 | 美国 | 2001-08-31 | |
| 口咽念珠菌病 | 临床2期 | 美国 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 念珠菌血症 positive culture | - | 蓋觸糧淵艱鏇齋鬱積鹽(襯鬱構艱憲襯築糧鬱觸) = 構製鑰簾夢遞壓餘廠鏇 夢鹹蓋蓋選顧積願襯範 (壓壓憲衊簾網夢醖壓積 ) 更多 | 积极 | 2024-09-26 | ||
蓋觸糧淵艱鏇齋鬱積鹽(襯鬱構艱憲襯築糧鬱觸) = 廠遞遞觸製糧蓋齋艱鏇 夢鹹蓋蓋選顧積願襯範 (壓壓憲衊簾網夢醖壓積 ) 更多 | |||||||
N/A | 21 | Topical capsofungin 0.5% | 醖齋積鹹願齋簾鏇艱襯(築築鑰鹽願襯繭襯衊糧) = 艱壓蓋鹽膚艱構淵鬱膚 鹹窪醖憲鹽艱顧顧積遞 (簾艱簾選築膚鬱襯憲願 ) | 积极 | 2022-09-29 | ||
Topical voriconazole 1% | 醖齋積鹹願齋簾鏇艱襯(築築鑰鹽願襯繭襯衊糧) = 淵範選製鏇艱願範齋構 鹹窪醖憲鹽艱顧顧積遞 (簾艱簾選築膚鬱襯憲願 ) | ||||||
临床3期 | 292 | Laboratory Biomarker Analysis+Caspofungin Acetate (Arm I (Caspofungin Acetate)) | 繭憲憲淵製遞齋鏇壓獵 = 蓋壓網憲淵鹹蓋廠膚衊 廠遞衊範築積壓遞鑰製 (齋齋鏇鏇衊窪淵製壓鹽, 膚鹽築膚蓋膚獵簾鹹繭 ~ 觸簾積築壓艱鑰簾觸獵) 更多 | - | 2021-01-07 | ||
(Arm II (Fluconazole or Voriconazole)) | 繭憲憲淵製遞齋鏇壓獵 = 築觸觸願網選淵鑰餘網 廠遞衊範築積壓遞鑰製 (齋齋鏇鏇衊窪淵製壓鹽, 衊範膚獵觸積淵構襯遞 ~ 憲壓鹽蓋齋壓願築願積) 更多 | ||||||
临床3期 | 290 | 願膚鹽齋鹹築壓築選鑰(構廠淵壓遞餘窪觸衊範) = 獵顧鏇鹽壓鑰築鬱壓衊 齋顧憲醖鹽餘鑰顧鏇糧 (繭繭膚顧網構壓餘築壓, 0.3% ~ 5.4%) | - | 2020-11-02 | |||
Triazole (fluconazole or voriconazole) | 願膚鹽齋鹹築壓築選鑰(構廠淵壓遞餘窪觸衊範) = 餘選鑰鬱遞鑰繭蓋齋膚 齋顧憲醖鹽餘鑰顧鏇糧 (繭繭膚顧網構壓餘築壓, 0.4% ~ 5.5%) | ||||||
N/A | - | 30 | Caspofungin 70 mg i.v. | 觸廠鏇願鏇襯鏇糧鹹製(觸築襯積壓醖獵範餘選) = 願鹹鬱選餘餘製糧選餘 築鹹獵顧鏇積憲淵鹽壓 (鬱膚夢鏇積獵構醖衊壓 ) | - | 2020-08-20 | |
Caspofungin 50 mg i.v. | 觸廠鏇願鏇襯鏇糧鹹製(觸築襯積壓醖獵範餘選) = 願壓襯簾鏇網繭襯襯範 築鹹獵顧鏇積憲淵鹽壓 (鬱膚夢鏇積獵構醖衊壓 ) | ||||||
N/A | 20 | (Low-AUC group) | 膚積窪衊築鹽顧遞簾鏇(鬱鬱壓範膚窪遞範鏇網) = 繭鏇艱醖簾網願夢鬱範 製蓋壓顧夢壓艱製鹽襯 (製襯願觸觸鏇遞糧鑰鏇 ) | - | 2020-05-01 | ||
(High-AUC group) | 膚積窪衊築鹽顧遞簾鏇(鬱鬱壓範膚窪遞範鏇網) = 鑰鏇餘淵壓膚範構選遞 製蓋壓顧夢壓艱製鹽襯 (製襯願觸觸鏇遞糧鑰鏇 ) | ||||||
临床2期 | 47 | 構醖鹹鹹遞鏇餘顧憲鬱(鬱廠醖艱齋築蓋壓鬱繭) = 製醖窪選淵顧齋顧積築 壓範製糧醖觸膚艱網築 (艱艱憲餘醖鹽鏇製鹽鑰 ) 更多 | 相似 | 2020-01-01 | |||
amphotericin B deoxycholate | 構醖鹹鹹遞鏇餘顧憲鬱(鬱廠醖艱齋築蓋壓鬱繭) = 廠窪醖繭積蓋餘窪積觸 壓範製糧醖觸膚艱網築 (艱艱憲餘醖鹽鏇製鹽鑰 ) 更多 | ||||||
临床3期 | 517 | 餘窪蓋餘鏇夢壓衊膚鹹(願壓鹽窪壓選簾鑰壓醖) = 簾鬱窪願醖遞夢膚範鏇 鬱醖鏇糧積網鏇淵餘餘 (觸獵蓋鏇蓋憲簾醖願膚 ) 更多 | - | 2019-11-05 | |||
餘窪蓋餘鏇夢壓衊膚鹹(願壓鹽窪壓選簾鑰壓醖) = 構築鏇鏇獵鹽鹹鹹繭壓 鬱醖鏇糧積網鏇淵餘餘 (觸獵蓋鏇蓋憲簾醖願膚 ) 更多 | |||||||
临床3期 | 517 | Laboratory Biomarker Analysis+Caspofungin Acetate (Arm I (Caspofungin Acetate)) | 淵築選鬱簾願構遞範網 = 選淵願鹽積鹽壓鹽觸蓋 蓋憲憲鏇襯鏇築鏇願鏇 (繭淵憲醖網積構餘醖艱, 膚蓋鹹鹽蓋願網製窪廠 ~ 繭襯構積窪選衊醖製築) 更多 | - | 2019-09-17 | ||
Laboratory Biomarker Analysis+Fluconazole (Arm II (Fluconazole)) | 淵築選鬱簾願構遞範網 = 鑰積膚製鑰鏇觸艱積範 蓋憲憲鏇襯鏇築鏇願鏇 (繭淵憲醖網積構餘醖艱, 遞衊願憲觸夢繭願構鏇 ~ 糧製膚鬱廠簾選繭餘壓) 更多 | ||||||
N/A | - | 84 | 觸築網醖鏇遞壓鏇鏇壓(鏇憲選蓋憲醖顧衊遞製) = 鏇壓襯鬱觸繭窪鹽選膚 繭網遞衊壓衊網窪構鬱 (願餘範鹽選壓觸夢觸襯, 11 ~ 28) 更多 | 积极 | 2018-11-19 | ||
蓋觸蓋膚廠夢鏇糧夢糧(簾齋構範觸衊選範選蓋) = 糧窪鏇鬱範蓋築鬱遞壓 蓋遞鹽鬱鹹窪壓觸襯選 (簾壓糧遞簾鹹選廠製鹹, 8 ~ 26) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用